Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Murata, Stephen ^a   Zhang, Catherine ^a   Finch, Nathan ^a   Zhang, Kevin ^b   Campo, Loredana ^a   Breuer, Eun Kyoung ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; AURORA A KINASE; BINDING PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE 12; E26 TRANSFORMATION SPECIFIC PROTEIN; FANCONI ANEMIA PROTEIN; GAMMA HISTONE H2AX; LYSINE SPECIFIC DEMETHYLASE 1; MICRORNA; MITOCHONDRIAL DNA; MRE11 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN P53; RAD51 PROTEIN; RUCAPARIB; SERINE THREONINE PROTEIN PHOSPHATASE; TALAZOPARIB; TRANSFORMING ACIDIC COILED COIL CONTAINING PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; VELIPARIB; XRCC1 PROTEIN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; GENOMIC SCAR; HUMAN; LETHALITY; NONHUMAN; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PREDICTOR VARIABLE; REVIEW; SCAR; ANIMAL; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; ENZYMOLOGY; EUROPE; FEMALE; FOOD AND DRUG ADMINISTRATION; HELA CELL LINE; MALE; METABOLISM; MOUSE; OVARIAN NEOPLASMS; PROCEDURES; TUMOR CELL LINE; UNITED STATES;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; EUROPE; FEMALE; HELA CELLS; HUMANS; MALE; MICE; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PRECISION MEDICINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84986001247     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/2346585     Document Type: Review

References (161)

1. Y. Liang, S.-Y. Lin, F. C. Brunicardi, J. Goss, and K. Li, "DNA damage response pathways in tumor suppression and cancer treatment," World Journal of Surgery, vol. 33, no. 4, pp. 661-666, 2009.
2. T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R. A. Sharma, "DNA repair pathways as targets for cancer therapy," Nature Reviews Cancer, vol. 8, no. 3, pp. 193-204, 2008.
3. H. Tian, Z. Gao, H. Li et al., "DNA damage response-a doubleedged sword in cancer prevention and cancer therapy," Cancer Letters, vol. 358, no. 1, pp. 8-16, 2015.
4. N. McCabe, N. C. Turner, C. J. Lord et al., "Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition," Cancer Research, vol. 66, no. 16, pp. 8109-8115, 2006.
5. W. G. Kaelin Jr., "The concept of synthetic lethality in the context of anticancer therapy," Nature Reviews Cancer, vol. 5, no. 9, pp. 689-698, 2005.
6. S. D. Merajver, T. S. Frank, J. Xu et al., "Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer," Clinical Cancer Research, vol. 1, no. 5, pp. 539-544, 1995.
7. K. Yoshida and Y. Miki, "Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage," Cancer Science, vol. 95, no. 11, pp. 866-871, 2004.
8. H. Konishi, M. Mohseni, A. Tamaki et al., "Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 43, pp. 17773-17778, 2011.
9. K. Yata, J.-Y. Bleuyard, R. Nakato et al., "BRCA2 coordinates the activities of cell-cycle kinases to promote genome stability," Cell Reports, vol. 7, no. 5, pp. 1547-1559, 2014.
10. S.M. H. Sy, M. S. Y. Huen, and J. Chen, "PALB2 is an integral component of the BRCA complex required for homologous recombination repair," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 17, pp. 7155-7160, 2009.
11. J. H. Houtgraaf, J. Versmissen, and W. J. van der Giessen, "A concise review of DNA damage checkpoints and repair in mammalian cells," Cardiovascular Revascularization Medicine, vol. 7, no. 3, pp. 165-172, 2006.
12. A. Ashworth, "A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair," Journal of Clinical Oncology, vol. 26, no. 22, pp. 3785-3790, 2008.
13. C. Underhill, M. Toulmonde, and H. Bonnefoi, "A review of PARP inhibitors: from bench to bedside," Annals of Oncology, vol. 22, no. 2, pp. 268-279, 2011.
14. B. Lupo and L. Trusolino, "Inhibition of poly(ADPribosyl) ation in cancer: old and new paradigms revisited," Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, vol. 1846, no. 1, pp. 201-215, 2014.
15. T. Helleday, "The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings," Molecular Oncology, vol. 5, no. 4, pp. 387-393, 2011.
16. S. Tangutoori, P. Baldwin, and S. Sridhar, "PARP inhibitors: a new era of targeted therapy," Maturitas, vol. 81, no. 1, pp. 5-9, 2015.
17. S. Kummar, A. M. Oza, G. F. Fleming et al., "Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer," Clinical Cancer Research, vol. 21, no. 7, pp. 1574-1582, 2015.
18. J. F. Liu, P. A. Konstantinopoulos, and U. A. Matulonis, "PARP inhibitors in ovarian cancer: current status and future promise," Gynecologic Oncology, vol. 133, no. 2, pp. 362-369, 2014.
19. T. D. Penning, G.-D. Zhu, V. B. Gandhi et al., "Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)- 2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer," Journal of Medicinal Chemistry, vol. 52, no. 2, pp. 514-523, 2009.
20. S.K. Sandhu, W. R. Schelman, G. Wilding et al., "Thepoly(ADPribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial," The Lancet Oncology, vol. 14, no. 9, pp. 882-892, 2013.
21. M. Ihnen, C. Z. Eulenburg, T. Kolarova et al., "Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer," Molecular Cancer Therapeutics, vol. 12, no. 6, pp. 1002-1015, 2013.
22. M. E. Moynahan, J.W. Chiu, B. H. Koller, and M. Jasint, "Brca1 controls homology-directed DNA repair," Molecular Cell, vol. 4, no. 4, pp. 511-518, 1999.
23. M. E. Moynahan, A. J. Pierce, and M. Jasin, "BRCA2 is required for homology-directed repair of chromosomal breaks," Molecular Cell, vol. 7, no. 2, pp. 263-272, 2001.
24. R. Wooster, S. L. Neuhausen, J. Mangion et al., "Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13," Science, vol. 265, no. 5181, pp. 2088-2090, 1994.
25. B. Kaufman, R. Shapira-Frommer, R. K. Schmutzler et al., "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation," Journal of Clinical Oncology, vol. 33, no. 3, pp. 244-250, 2015.
26. A. Tutt, M. Robson, J. E. Garber et al., "Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-ofconcept trial," The Lancet, vol. 376, no. 9737, pp. 235-244, 2010.
27. K. A. Gelmon, M. Tischkowitz, H. Mackay et al., "Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study," The Lancet Oncology, vol. 12, no. 9, pp. 852-861, 2011.
28. R. Buisson, A.-M. Dion-Côté, Y. Coulombe et al., "Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination," Nature Structural and Molecular Biology, vol. 17, no. 10, pp. 1247-1254, 2010.
29. N. Rahman, S. Seal, D. Thompson et al., "PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene," Nature Genetics, vol. 39, no. 2, pp. 165-167, 2007.
30. K. Obermeier, J. Sachsenweger, T. W. P. Friedl, H. Pospiech, R. Winqvist, and L. Wiesmüller, "Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into errorprone pathways in breast cancer patients," Oncogene, vol. 35, pp. 3796-3806, 2016.
31. D. B. Zhen, K. G. Rabe, S. Gallinger et al., "BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study," Genetics in Medicine, vol. 17, no. 7, pp. 569-577, 2015.
32. W. Duan, L. Gao, B. Aguila, A. Kalvala, G. A. Otterson, and M. A. Villalona-Calero, "Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer," Frontiers in Oncology, vol. 4, article 368, 2014.
33. I. Garcia-Higuera, T. Taniguchi, S. Ganesan et al., "Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway," Molecular Cell, vol. 7, no. 2, pp. 249-262, 2001.
34. X. Wang, P. R. Andreassen, and A. D. D'Andrea, "Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin," Molecular and Cellular Biology, vol. 24, no. 13, pp. 5850-5862, 2004.
35. H. Willers, A. G. Taghian, C.-M. Luo, A. Treszezamsky, D. C. Sgroi, and S. N. Powell, "Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies," Molecular Cancer Research, vol. 7, no. 8, pp. 1304-1309, 2009.
36. M. R. G. Taylor, M. Špírek, K. R. Chaurasiya et al., "Rad51 paralogs remodel pre-synaptic Rad51 filaments to stimulate homologous recombination," Cell, vol. 162, no. 2, pp. 271-286, 2015.
37. R. Scully, J. Chen, A. Plug et al., "Association of BRCA1 with Rad51 in mitotic and meiotic cells," Cell, vol. 88, no. 2, pp. 265-275, 1997.
38. L. Pellegrini, D. S. Yu, T. Lo et al., "Insights into DNA recombination from the structure of a RAD51-BRCA2 complex," Nature, vol. 420, no. 6913, pp. 287-293, 2002.
39. E. Raderschall, E. I. Golub, and T. Haaf, "Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 5, pp. 1921-1926, 1999.
40. T. Haaf, E. I. Golub, G. Reddy, C. M. Radding, and D. C. Ward, "Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes," Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 6, pp. 2298-2302, 1995.
41. H. Asakawa, H. Koizumi, A. Koike et al., "Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins," Breast Cancer Research, vol. 12, no. 2, article R17, 2010.
42. M. Graeser, A. McCarthy, C. J. Lord et al., "A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer," Clinical Cancer Research, vol. 16, no. 24, pp. 6159-6168, 2010.
43. A. Min, S.-A. Im, Y.-K. Yoon et al., "RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib," Molecular Cancer Therapeutics, vol. 12, no. 6, pp. 865-877, 2013.
44. A. Mukhopadhyay, A. Elattar, A. Cerbinskaite et al., "Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors," Clinical Cancer Research, vol. 16, no. 8, pp. 2344-2351, 2010.
45. S. V. Kozlov, A. J. Waardenberg, K. Engholm-Keller, J. W. Arthur, M. E. Graham, and M. F. Lavin, "Reactive Oxygen Species (ROS)-activated ATM-dependent phosphorylation of cytoplasmic substrates identified by large-scale phosphoproteomics screen," Molecular & Cellular Proteomics, vol. 15, no. 3, pp. 1032-1047, 2016.
46. C. T. Williamson, H. Muzik, A. G. Turhan et al., "ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADPribose) polymerase-1 inhibitors," Molecular Cancer Therapeutics, vol. 9, no. 2, pp. 347-357, 2010.
47. E. Kubota, C. T. Williamson, R. Ye et al., "Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines," Cell Cycle, vol. 13, no. 13, pp. 2129-2137, 2014.
48. P. Kalev, M. Simicek, I. Vazquez et al., "Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition," Cancer Research, vol. 72, no. 24, pp. 6414-6424, 2012.
49. R. S. Williams, J. S. Williams, and J. A. Tainer, "Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template," Biochemistry and Cell Biology, vol. 85, no. 4, pp. 509-520, 2007.
50. R. Koppensteiner, E. P. Samartzis, A. Noske et al., "Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro," PLoS ONE, vol. 9, no. 6, Article ID e100041, 2014.
51. S. A. Lajud, D. A. Nagda, T. Yamashita et al., "Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer," Clinical Cancer Research, vol. 20, no. 24, pp. 6465-6478, 2014.
52. T. J. Gaymes, A. M. Mohamedali, M. Patterson et al., "Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADPribose) polymerase inhibitors in myeloid malignancies," Haematologica, vol. 98, no. 9, pp. 1397-1406, 2013.
53. H. C. Reinhardt and B. Schumacher, "The p53 network: cellular and systemic DNA damage responses in aging and cancer," Trends in Genetics, vol. 28, no. 3, pp. 128-136, 2012.
54. H. Holstege, H. M. Horlings, A. Velds et al., "BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations," BMC Cancer, vol. 10, article 654, 2010.
55. T. M. Severson, J. Peeters, I. Majewski et al., "BRCA1-like signature in triple negative breast cancer:molecular and clinical characterization reveals subgroups with therapeutic potential," Molecular Oncology, vol. 9, no. 8, pp. 1528-1538, 2015.
56. I. C. R. Ireno, R. S. T. Wiehe, A. I. U. Stahl et al., "Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53," Carcinogenesis, vol. 35, no. 10, pp. 2273-2282, 2014.
57. Y. Atsumi, Y. Minakawa, M. Ono et al., "ATM and SIRT6/SNF2H mediate transient H2AX stabilization when DSBs form by blocking HUWE1 to allow efficient γH2AX foci formation," Cell Reports, vol. 13, no. 12, pp. 2728-2740, 2015.
58. L. J. Kuo and L.-X. Yang, "γ-H2AX-a novel biomaker for DNA double-strand breaks," In Vivo, vol. 22, no. 3, pp. 305-309, 2008.
59. I. Faraoni, M. Compagnone, S. Lavorgna et al., "BRCA1, PARP1 and γH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparib," Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1852, no. 3, pp. 462-472, 2015.
60. S. Kummar, J. Ji, R. Morgan et al., "A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas," Clinical Cancer Research, vol. 18, no. 6, pp. 1726-1734, 2012.
61. S. Kummar, A. Chen, J. Ji et al., "Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas," Cancer Research, vol. 71, no. 17, pp. 5626-5634, 2011.
62. V. Schreiber, F. Dantzer, J.-C. Amé, and G. De Murcia, "Poly(ADP-ribose): novel functions for an old molecule," Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 517-528, 2006.
63. C. E. Redon, A. J. Nakamura, Y.-W. Zhang et al., "Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers," Clinical Cancer Research, vol. 16, no. 18, pp. 4532-4542, 2010.
64. M. Y. Kim, T. Zhang, and W. L. Kraus, "Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal," Genes & Development, vol. 19, no. 17, pp. 1951-1967, 2005.
65. S. Nowsheen, J. A. Bonner, and E. S. Yang, "The poly(ADPribose) polymerase inhibitor ABT-888 reduces radiationinduced nuclear EGFR and augments head and neck tumor response to radiotherapy," Radiotherapy and Oncology, vol. 99, no. 3, pp. 331-338, 2011.
66. L. Piao, H. Nakagawa, K. Ueda et al., "C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage," Genes Chromosomes and Cancer, vol. 50, no. 1, pp. 13-24, 2011.
67. C. E. Ström, F. Johansson, M. Uhlén, C. A.-K. Szigyarto, K. Erixon, and T. Helleday, "Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate," Nucleic Acids Research, vol. 39, no. 8, pp. 3166-3175, 2011.
68. R. Sultana, T. Abdel-Fatah, R. Abbotts et al., "Targeting XRCC1 deficiency in breast cancer for personalized therapy," Cancer Research, vol. 73, no. 5, pp. 1621-1634, 2013.
69. J. K. Horton, D. F. Stefanick, R. Prasad, N. R. Gassman, P. S. Kedar, and S. H. Wilson, "Base excision repair defects invoke hypersensitivity to PARP inhibition," Molecular Cancer Research, vol. 12, no. 8, pp. 1128-1139, 2014.
70. C. J. Lord, S. McDonald, S. Swift, N. C. Turner, and A. Ashworth, "A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity," DNA Repair, vol. 7, no. 12, pp. 2010-2019, 2008.
71. J. Dittmer, "The role of the transcription factor Ets1 in carcinoma," Seminars in Cancer Biology, vol. 35, pp. 20-38, 2015.
72. S. Singh, J. Barrett, K. Sakata, R. G. Tozer, and G. Singh, "ETS proteins and MMPs: partners in invasion and metastasis," Current Drug Targets, vol. 3, no. 5, pp. 359-367, 2002.
73. J. C. Brenner and A. M. Chinnaiyan, "Translocations in epithelial cancers," Biochimica et Biophysica Acta, vol. 1796, no. 2, pp. 201-215, 2009.
74. K. M. Baker, G. Wei, A. E. Schaffner, and M. C. Ostrowski, "Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter," The Journal of Biological Chemistry, vol. 278, no.20, pp. 17876-17884, 2003.
75. V. Puzovic, I. Brcic, I. Ranogajec, and J. Jakic-Razumovic, "Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients," Neoplasma, vol. 61, no. 4, pp. 439-446, 2014.
76. A. J. Legrand, S. Choul-Li, C. Spriet et al., "The level of Ets-1 protein is regulated by poly(ADP-ribose) polymerase-1 (PARP-1) in cancer cells to prevent DNA damage," PLoS ONE, vol. 8, no. 2, Article ID e55883, 2013.
77. L. Liu, W. Zhou, C.-T. Cheng et al., "TGFβ Induces 'bRCAness' and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes," Molecular Cancer Research, vol. 12, no. 11, pp. 1597-1609, 2014.
78. M. D. Paraskevopoulou and A. G. Hatzigeorgiou, "Analyzing MiRNA-Lnc RNA interactions," Methods in Molecular Biology, vol. 1402, pp. 271-286, 2016.
79. A. Bisso, M. Faleschini, F. Zampa et al., "Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer," Cell Cycle, vol. 12, no. 11, pp. 1679-1687, 2013.
80. P. Moskwa, F. M. Buffa, Y. Pan et al., "MiR-182-mediated downregulation of BRCA1 Impacts DNA repair and sensitivity to PARP inhibitors," Molecular Cell, vol. 41, no. 2, pp. 210-220, 2011.
81. S. Neijenhuis, I. Bajrami, R. Miller, C. J. Lord, and A. Ashworth, "Identification of miRNA modulators to PARP inhibitor response," DNA Repair, vol. 12, no. 6, pp. 394-402, 2013.
82. J.-W. Huang, Y. Wang, K. K. Dhillon et al., "Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity," Molecular Cancer Research, vol. 11, no. 12, pp. 1564-1573, 2013.
83. Y. Wang, J.-W. Huang, P. Calses, C. J. Kemp, and T. Taniguchi, "MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition," Cancer Research, vol. 72, no. 16, pp. 4037-4046, 2012.
84. S. Lim, A. Janzer, A. Becker et al., "Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology," Carcinogenesis, vol. 31, no. 3, pp. 512-520, 2010.
85. N. Serce, A. Gnatzy, S. Steiner, H. Lorenzen, J. Kirfel, and R. Buettner, "Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast," BMC Clinical Pathology, vol. 12, article 13, 2012.
86. N. Mosammaparast, H. Kim, B. Laurent et al., "The histone demethylase LSD1/KDM1A promotes the DNA damage response," The Journal of Cell Biology, vol. 203, no. 3, pp. 457-470, 2013.
87. S. Nagasawa, A. S. Sedukhina, Y. Nakagawa et al., "LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition," PLoS ONE, vol. 10, no. 2, Article ID e0118002, 2015.
88. D. Blazek, J. Kohoutek, K. Bartholomeeusen et al., "The cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes," Genes & Development, vol. 25, no. 20, pp. 2158-2172, 2011.
89. D. Vrábel, M. Svoboda, J. Navrátil, and J. Kohoutek, "Function of CDK12 in tumor initiation and progression and its clinical consequences," Klinicka Onkologie, vol. 27, no. 5, pp. 340-346, 2014.
90. P. M. Joshi, S. L. Sutor, C. J. Huntoon, and L. M. Karnitz, "Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors," The Journal of Biological Chemistry, vol. 289, no. 13, pp. 9247-9253, 2014.
91. I. Bajrami, J. R. Frankum, A. Konde et al., "Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity," Cancer Research, vol. 74, no. 1, pp. 287-297, 2014.
92. I. Peset and I. Vernos, "The TACC proteins: TACC-ling microtubule dynamics and centrosome function," Trends in Cell Biology, vol. 18, no. 8, pp. 379-388, 2008.
93. P. Singh, G. E. Thomas, K. K. Gireesh, and T.K. Manna, "TACC3 protein regulates microtubule nucleation by affecting γ-tubulin ring complexes," Journal of Biological Chemistry, vol. 289, no.46, pp. 31719-31735, 2014.
94. B. U. Nwagbara, A. E. Faris, E. A. Bearce et al., "TACC3 is a microtubule plus end-tracking protein that promotes axon elongation and also regulates microtubule plus end dynamics in multiple embryonic cell types," Molecular Biology of the Cell, vol. 25, no. 21, pp. 3350-3362, 2014.
95. I. H. Still, P. Vince, and J. K. Cowell, "The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines," Genomics, vol. 58, no. 2, pp. 165-170, 1999.
96. G.-H. Ha, J.-L. Kim, and E.-K. Y. Breuer, "TACC3 is essential for EGF-mediated EMT in cervical cancer," PLoS ONE, vol. 8, no. 8, article e70353, 2013.
97. G.-H. Ha, J.-L. Kim, A. Petersson et al., "TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition," Oncogene, 2014.
98. T. Sourisseau, D. Maniotis, A. McCarthy et al., "Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition," EMBO Molecular Medicine, vol. 2, no. 4, pp. 130-142, 2010.
99. M. Cazales, E. Schmitt, E. Montembault, C. Dozier, C. Prigent, and B. Ducommun, "CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage," Cell Cycle, vol. 4, no. 9, pp. 1233-1238, 2005.
100. Z. Wang, Y. Liu, L. Lu et al., "Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis," Oncotarget, vol. 6, no. 9, pp. 6670-6683, 2015.
101. J. M. Sun, L. N. Yang, H. Xu, B. Chang, H. Y. Wang, and G. Yang, "Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells," American Journal of Cancer Research, vol. 5, no. 3, pp. 1133-1145, 2015.
102. J. R. Bischoff, L. Anderson, Y. Zhu et al., "A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers," EMBO Journal, vol. 17, no. 11, pp. 3052-3065, 1998.
103. J.-L. Liu, Z. Mao, T. A. LaFortune et al., "Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade," Cancer Research, vol. 67, no. 22, pp. 11054-11063, 2007.
104. J. Olasz, Z. Doleschall, Z. Dunai, A. Pazsitka, and O. Csuka, "PI3K/AKT pathway activation and therapeutic consequences in breast cancer," Magyar Onkologia, vol. 59, no. 4, pp. 346-351, 2015.
105. V. Nodouzi, M. Nowroozi, M. Hashemi, G. Javadi, and R. Mahdian, "Concurrent down-regulation of PTEN and NKX3.1 expression in Iranian patients with prostate cancer," The International Brazilian Journal of Urology, vol. 41, no. 5, pp. 898-905, 2015.
106. W. H. Shen, A. S. Balajee, J. Wang et al., "Essential Role for Nuclear PTEN inmaintaining chromosomal integrity," Cell, vol. 128, no. 1, pp. 157-170, 2007.
107. A.M. Mendes-Pereira, S. A. Martin, R. Brough et al., "Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors," EMBO Molecular Medicine, vol. 1, no. 6-7, pp. 315-322, 2009.
108. J.-S. Kim, C. Lee, C. L. Bonifant, H. Ressom, and T. Waldman, "Activation of p53-dependent growth suppression in human cells bymutations in PTEN or PIK3CA," Molecular and Cellular Biology, vol. 27, no. 2, pp. 662-677, 2007.
109. J. Puc and R. Parsons, "PTENloss inhibits CHK1 tocausedouble stranded-DNA breaks in cells," Cell Cycle, vol. 4, no. 7, pp. 927-929, 2005.
110. M. Fraser, H. Zhao, K. R. Luoto et al., "PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy," Clinical Cancer Research, vol. 18, no. 4, pp. 1015-1027, 2012.
111. C. R. Hunt, A. Gupta, N. Horikoshi, and T. K. Pandita, "Does PTEN loss impair DNA double-strand break repair by homologous recombination?" Clinical Cancer Research, vol. 18, no. 4, pp. 920-922, 2012.
112. A. A. Arbini, F. Guerra, M. Greco et al., "Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2," Oncogenesis, vol. 2, article e82, 2013.
113. J. A. Watkins, S. Irshad, A. Grigoriadis, and A. N. J. Tutt, "Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers," Breast Cancer Research, vol. 16, no. 3, article 211, 2014.
114. S. Rottenberg, J. E. Jaspers, A. Kersbergen et al., "High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 44, pp. 17079-17084, 2008.
115. T. Popova, E. Manié, G. Rieunier et al., "Ploidy and largescale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation," Cancer Research, vol. 72, no. 21, pp. 5454-5462, 2012.
116. J. B. Geigl, A. C. Obenauf, T. Schwarzbraun, and M. R. Speicher, "Defining 'chromosomal instability'," Trends in Genetics, vol. 24, no. 2, pp. 64-69, 2008.
117. H. Farmer, H. McCabe, C. J. Lord et al., "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy," Nature, vol. 434, no. 7035, pp. 917-921, 2005.
118. I. Ibragimova and P. Cairns, "Assays for hypermethylation of the BRCA1 gene promoter in Tumor cells to predict sensitivity to PARP-Inhibitor therapy," Methods in Molecular Biology, vol. 780, pp. 277-291, 2011.
119. J. Veeck, S. Ropero, F. Setien et al., "BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors," Journal of Clinical Oncology, vol. 28, no. 29, pp. e563-e566, 2010.
120. M. Esteller, J. M. Silva, G. Dominguez et al., "Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors," Journal of the National Cancer Institute, vol. 92, no. 7, pp. 564-569, 2000.
121. Y. Drew, E. A. Mulligan, W.-T. Vong et al., "Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers withmutated or methylated BRCA1 or BRCA2," Journal of the National Cancer Institute, vol. 103, no. 4, pp. 334-346, 2011.
122. A. L. Bane, A. M. Mulligan, D. Pinnaduwage, F. P. O'Malley, and I. L. Andrulis, "EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry," Breast Cancer Research and Treatment, vol. 127, no. 3, pp. 831-839, 2011.
123. S. K. Pal and J. Mortimer, "Triple-negative breast cancer: novel therapies and new directions," Maturitas, vol. 63, no. 4, pp. 269-274, 2009.
124. N. C. Turner, C. J. Lord, E. Iorns et al., "A synthetic lethal siRNA screen identifying genesmediating sensitivity to a PARP inhibitor," The EMBO Journal, vol. 27, no. 9, pp. 1368-1377, 2008.
125. M. W. Audeh, J. Carmichael, R. T. Penson et al., "Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2mutations and recurrent ovarian cancer: a proof-of-concept trial," The Lancet, vol. 376, no. 9737, pp. 245-251, 2010.
126. X. Wang and D. T. Weaver, "The ups and downs of DNA repair biomarkers for PARP inhibitor therapies," American Journal of Cancer Research, vol. 1, no. 3, pp. 301-327, 2011.
127. X. W. Meng, B. D. Koh, J.-S. Zhang et al., "Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptormediated apoptosis by enhancing death receptor expression," The Journal of Biological Chemistry, vol. 289, no. 30, pp. 20543-20558, 2014.
128. M. I. Rodríguez, A. González-Flores, F. Dantzer, J. Collard, A. G. De Herreros, and F. J. Oliver, "Poly(ADP-ribose)-dependent regulation of Snail1 protein stability," Oncogene, vol. 30, no. 42, pp. 4365-4372, 2011.
129. S.-W. Yu, S. A. Andrabi, H. Wang et al., "Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 48, pp. 18314-18319, 2006.
130. M. I. Rodríguez, A. Peralta-Leal, F. O'Valle et al., "PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation," PLoS Genetics, vol. 9, no. 6, article e1003531, 2013.
131. N. Chan, I. M. Pires, Z. Bencokova et al., "Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment," Cancer Research, vol. 70, no. 20, pp. 8045-8054, 2010.
132. A. Pyriochou, G. Olah, E. A. Deitch, C. Szabó, and A. Papapetropoulos, "Inhibition of angiogenesis by the poly(ADPribose) polymerase inhibitor PJ-34," International Journal of Molecular Medicine, vol. 22, no. 1, pp. 113-118, 2008.
133. L. Tentori, P. M. Lacal, A. Muzi et al., "Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis," European Journal of Cancer, vol. 43, no. 14, pp. 2124-2133, 2007.
134. M. Rajesh, P. Mukhopadhyay, S. Bátkai et al., "Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis," Biochemical and Biophysical Research Communications, vol. 350, no. 2, pp. 352-357, 2006.
135. N. Chan, M. Koritzinsky, H. Zhao et al., "Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance," Cancer Research, vol. 68, no. 2, pp. 605-614, 2008.
136. V. M. Neumeister, C. A. Sullivan, R. Lindner et al., "Hypoxiainduced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer," Breast Cancer Research and Treatment, vol. 136, no. 1, pp. 67-75, 2012.
137. K. R. Luoto, R. Kumareswaran, and R. G. Bristow, "Tumor hypoxia as a driving force in genetic instability," Genome Integrity, vol. 4, article 5, 2013.
138. S. J. Hill, A. P. Clark, D. P. Silver, and D. M. Livingston, "BRCA1 pathway function in basal-like breast cancer cells," Molecular and Cellular Biology, vol. 34, no. 20, pp. 3828-3842, 2014.
139. G. Illuzzi, E. Fouquerel, J.-C. Amé et al., "PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress," Nucleic Acids Research, vol. 42, no. 12, pp. 7776-7792, 2014.
140. J. Luo, N. L. Solimini, and S. J. Elledge, "Principles of cancer therapy: oncogene and non-oncogene addiction," Cell, vol. 136, no. 5, pp. 823-837, 2009.
141. J. M. Stommel, A. C. Kimmelman, H. Ying et al., "Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies," Science, vol. 318, no. 5848, pp. 287-290, 2007.
142. V. Schreiber, F. Dantzer, J.-C. Amé, and G. de Murcia, "Poly(ADP-ribose): novel functions for an old molecule," Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 517-528, 2006.
143. C. E. Redon, A. J. Nakamura, Y.-W. Zhang et al., "Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers," Clinical Cancer Research, vol. 16, no. 18, pp. 4532-4542, 2010.
144. P. Gottipati, B. Vischioni, N. Schultz et al., "Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells," Cancer Research, vol. 70, no. 13, pp. 5389-5398, 2010.
145. L. Liu, W. Zhou, C.-T. Cheng et al., "TGFβ Induces 'bRCAness' and Sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes," Molecular Cancer Research, vol. 12, no. 11, pp. 1597-1609, 2014.
146. Y. Wang, Y. Yu, A. Tsuyada et al., "Transforming growth factor-B regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM," Oncogene, vol. 30, no. 12, pp. 1470-1480, 2011.
147. L. Hughes-Davies, D. Huntsman, M. Ruas et al., "EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer," Cell, vol. 115, no. 5, pp. 523-535, 2003.
148. I. Cousineau and A. Belmaaza, "EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases," Molecular Genetics and Genomics, vol. 285, no. 4, pp. 325-340, 2011.
149. P. M. Wilkerson, K. J. Dedes, D. Wetterskog et al., "Functional characterization of EMSY gene amplification in human cancers," The Journal of Pathology, vol. 225, no. 1, pp. 29-42, 2011.
150. S. M. Domchek, C. Aghajanian, R. Shapira-Frommer et al., "Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy," Gynecologic Oncology, vol. 140, no. 2, pp. 199-203, 2016.
151. J. Ledermann, P. Harter, C. Gourley et al., "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial," The Lancet Oncology, vol. 15, no. 8, pp. 852-861, 2014.
152. BMN673 (Talazoparib), an Oral PARP Inhibitor, in People with Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment, May 2016, https://clinicaltrials.gov/ct2/show/NCT02326844?term=talazoparib& rank=9.
153. A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients with BRCA Mutation (EMBRACA Study), (EMBRACA), May 2016, https://clinicaltrials.gov/ct2/show/NCT01945775?term=talazoparib& rank=8.
154. Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients with Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors, October 2015, https://clinicaltrials.gov/ct2/show/NCT01326702?term=veliparib& rank=10.
155. Veliparib and Topotecan for Relapsed Ovarian Cancer with Negative or Unknown BRCA Status, June 2015, https://clinicaltrials.gov/ct2/show/NCT01690598?term=veliparib&rank=22.
156. Gemcitabine Hydrochloride and Cisplatin with or Without Veliparib or Veliparib Alone in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer, June 2016, https://clinicaltrials.gov/ct2/show/NCT01585805?term=nct01585805& rank=1.
157. A Study of Rucaparib in Patients with Pancreatic Cancer and a Known Deleterious BRCA Mutation, December 2015, https://clinicaltrials.gov/ct2/show/NCT02042378?term=rucaparib& rank=1.
158. A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3), April 2016, https://clinicaltrials.gov/ct2/show/NCT01968213? term=rucaparib&rank=3.
159. ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients with Previously Treated, Incurable Ewing Sarcoma, May 2016, https://clinicaltrials.gov/ct2/show/NCT02044120?term=niraparib&rank=7.
160. "A phase III trial of niraparib versus physician's choice in HER2 negative, germline BRCA mutation-positive breast cancer patients (BRAVO)," https://clinicaltrials.gov/ct2/show/NCT01905592?term=niraparib&rank=6.
161. A Study of Niraparib in Patients with Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens, January 2016, https://clinicaltrials.gov/ct2/show/NCT02354586?term=niraparib&rank=5.